Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 48
- Registration Number
- NCT00634751
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 18
- Registration Number
- NCT00632541
- Locations
- 🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Arnett Cancer Care, Lafayette, Indiana, United States
🇺🇸Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- British Columbia Cancer Agency
- Registration Number
- NCT00627835
- Locations
- 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 55
- Registration Number
- NCT00623402
- Locations
- 🇩🇪
Dpt. of Dermatology, University of Hannover, Hannover, Germany
🇩🇪Dpt. of Dermatology, Humboldt University, Berlin, Germany
🇩🇪Dept. of Dermatology, Elbe Klinikum, Buxtehude, Germany
TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 43
- Registration Number
- NCT00618384
- Locations
- 🇩🇪
Medizinische Universitätsklinik Ulm Innere Medizin I, Ulm, BW, Germany
🇩🇪Klinikum der Universität Großhardern, Muenchen, BY, Germany
🇩🇪Klinikum der Johann-Goethe-Universität, Frankfurt, HE, Germany
The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT00619242
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 12
- Registration Number
- NCT00609934
- Locations
- 🇨🇦
Princess Margaret Hosptial, Toronto, Ontario, Canada
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT00609804
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
A Study of Radiation With Sorafenib in Advanced Cancer
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 34
- Registration Number
- NCT00610246
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 57
- Registration Number
- NCT00606866
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.